Abstract
Metastatic spinal cord compression (mscc) is an oncologic emergency that, unless diagnosed early and treated appropriately, can lead to permanent neurologic impairment. After an analysis of relevant studies evaluating the effectiveness of various treatment modalities, the Comité de l'évolution des pratiques en oncologie (cepo) made recommendations on mscc management. A review of the scientific literature published up to February 2011 considered only phase ii and iii trials that included assessment of neurologic function. A total of 26 studies were identified. Considering the evidence available to date, cepo recommends that cancer patients with mscc be treated by a specialized multidisciplinary team.dexamethasone 16 mg daily be administered to symptomatic patients as soon as mscc is diagnosed or suspected.high-loading-dose corticosteroids be avoided.histopathologic diagnosis and scores from scales evaluating prognosis and spinal instability be considered before treatment.corticosteroids and chemotherapy with radiotherapy be offered to patients with spinal cord compression caused by myeloma, lymphoma, or germ cell tumour without sign of spinal instability or compression by bone fragment.short-course radiotherapy be administered to patients with spinal cord compression and short life expectancy.long-course radiotherapy be administered to patients with inoperable spinal cord compression and good life expectancy.decompressive surgery followed by long-course radiotherapy be offered to appropriate symptomatic mscc patients (including spinal instability, displacement of vertebral fragment); andpatients considered for surgery have a life expectancy of at least 3-6 months.
Highlights
According to recent Canadian statistics, an estimated 186,400 new cases of cancer and 75,700 deaths from cancer are expected in Canada in 20121
The scientific literature published up to February 2011 was reviewed through a PubMed search using the keywords “metastatic spinal cord compression”, “neoplasm”, “cancer,” “treatment,” “surgery,” “radiotherapy,” and “corticotherapy.” Only prospective studies including an evaluation of neurologic function, in the English or French language, were considered
Patients with an established diagnosis of cancer presenting with spinal cord compression be treated by a specialized multidisciplinary team
Summary
According to recent Canadian statistics, an estimated 186,400 new cases of cancer and 75,700 deaths from cancer are expected in Canada in 20121. The spine is the most common site for bone metastasis, affecting up to 30% of cancer patients[3]. Between 5% and 10% of cancer patients will develop metastatic spinal cord compression (mscc), an oncologic emergency requiring early diagnosis and immediate treatment[4,5]. Spinal cord damage including vascular injury, hemorrhage, white matter edema, and nerve damage such as demyelination and axonal damage, are frequently observed at the site of compression and cause symptoms such as back pain and motor or sensory deficits[6,7,8,9]. Metastatic spinal cord compression (mscc) is an oncologic emergency that, unless diagnosed early and treated appropriately, can lead to permanent neurologic impairment. After an analysis of relevant studies evaluating the effectiveness of various treatment modalities, the Comité de l’évolution des pratiques en oncologie (cepo) made recommendations on mscc management
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
